291 related articles for article (PubMed ID: 16026621)
1. Inhibition of Henipavirus fusion and infection by heptad-derived peptides of the Nipah virus fusion glycoprotein.
Bossart KN; Mungall BA; Crameri G; Wang LF; Eaton BT; Broder CC
Virol J; 2005 Jul; 2():57. PubMed ID: 16026621
[TBL] [Abstract][Full Text] [Related]
2. Molecular determinants of antiviral potency of paramyxovirus entry inhibitors.
Porotto M; Carta P; Deng Y; Kellogg GE; Whitt M; Lu M; Mungall BA; Moscona A
J Virol; 2007 Oct; 81(19):10567-74. PubMed ID: 17652384
[TBL] [Abstract][Full Text] [Related]
3. Receptor binding, fusion inhibition, and induction of cross-reactive neutralizing antibodies by a soluble G glycoprotein of Hendra virus.
Bossart KN; Crameri G; Dimitrov AS; Mungall BA; Feng YR; Patch JR; Choudhary A; Wang LF; Eaton BT; Broder CC
J Virol; 2005 Jun; 79(11):6690-702. PubMed ID: 15890907
[TBL] [Abstract][Full Text] [Related]
4. Henipavirus mediated membrane fusion, virus entry and targeted therapeutics.
Steffen DL; Xu K; Nikolov DB; Broder CC
Viruses; 2012 Feb; 4(2):280-308. PubMed ID: 22470837
[TBL] [Abstract][Full Text] [Related]
5. Functional Analysis of the Fusion and Attachment Glycoproteins of Mojiang Henipavirus.
Cheliout Da Silva S; Yan L; Dang HV; Xu K; Epstein JH; Veesler D; Broder CC
Viruses; 2021 Mar; 13(3):. PubMed ID: 33809833
[TBL] [Abstract][Full Text] [Related]
6. Developments towards effective treatments for Nipah and Hendra virus infection.
Bossart KN; Broder CC
Expert Rev Anti Infect Ther; 2006 Feb; 4(1):43-55. PubMed ID: 16441208
[TBL] [Abstract][Full Text] [Related]
7. Peptides corresponding to the heptad repeat sequence of human parainfluenza virus fusion protein are potent inhibitors of virus infection.
Yao Q; Compans RW
Virology; 1996 Sep; 223(1):103-12. PubMed ID: 8806544
[TBL] [Abstract][Full Text] [Related]
8. Surface glycoproteins of the recently identified African Henipavirus promote viral entry and cell fusion in a range of human, simian and bat cell lines.
Lawrence P; Escudero Pérez B; Drexler JF; Corman VM; Müller MA; Drosten C; Volchkov V
Virus Res; 2014 Mar; 181():77-80. PubMed ID: 24452140
[TBL] [Abstract][Full Text] [Related]
9. Membrane fusion tropism and heterotypic functional activities of the Nipah virus and Hendra virus envelope glycoproteins.
Bossart KN; Wang LF; Flora MN; Chua KB; Lam SK; Eaton BT; Broder CC
J Virol; 2002 Nov; 76(22):11186-98. PubMed ID: 12388678
[TBL] [Abstract][Full Text] [Related]
10. A recombinant Cedar virus based high-throughput screening assay for henipavirus antiviral discovery.
Amaya M; Cheng H; Borisevich V; Navaratnarajah CK; Cattaneo R; Cooper L; Moore TW; Gaisina IN; Geisbert TW; Rong L; Broder CC
Antiviral Res; 2021 Sep; 193():105084. PubMed ID: 34077807
[TBL] [Abstract][Full Text] [Related]
11. Viral entry inhibitors targeted to the membrane site of action.
Porotto M; Yokoyama CC; Palermo LM; Mungall B; Aljofan M; Cortese R; Pessi A; Moscona A
J Virol; 2010 Jul; 84(13):6760-8. PubMed ID: 20357085
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of Nipah virus infection in vivo: targeting an early stage of paramyxovirus fusion activation during viral entry.
Porotto M; Rockx B; Yokoyama CC; Talekar A; Devito I; Palermo LM; Liu J; Cortese R; Lu M; Feldmann H; Pessi A; Moscona A
PLoS Pathog; 2010 Oct; 6(10):e1001168. PubMed ID: 21060819
[TBL] [Abstract][Full Text] [Related]
13. Ephrin-B2 ligand is a functional receptor for Hendra virus and Nipah virus.
Bonaparte MI; Dimitrov AS; Bossart KN; Crameri G; Mungall BA; Bishop KA; Choudhry V; Dimitrov DS; Wang LF; Eaton BT; Broder CC
Proc Natl Acad Sci U S A; 2005 Jul; 102(30):10652-7. PubMed ID: 15998730
[TBL] [Abstract][Full Text] [Related]
14. Henipavirus pathogenesis and antiviral approaches.
Mathieu C; Horvat B
Expert Rev Anti Infect Ther; 2015 Mar; 13(3):343-54. PubMed ID: 25634624
[TBL] [Abstract][Full Text] [Related]
15. A functional henipavirus envelope glycoprotein pseudotyped lentivirus assay system.
Khetawat D; Broder CC
Virol J; 2010 Nov; 7():312. PubMed ID: 21073718
[TBL] [Abstract][Full Text] [Related]
16. Identification of a broad-spectrum antiviral small molecule against severe acute respiratory syndrome coronavirus and Ebola, Hendra, and Nipah viruses by using a novel high-throughput screening assay.
Elshabrawy HA; Fan J; Haddad CS; Ratia K; Broder CC; Caffrey M; Prabhakar BS
J Virol; 2014 Apr; 88(8):4353-65. PubMed ID: 24501399
[TBL] [Abstract][Full Text] [Related]
17. Detailed Molecular Biochemistry for Novel Therapeutic Design Against Nipah and Hendra Virus: A Systematic Review.
Bhattacharya S; Dhar S; Banerjee A; Ray S
Curr Mol Pharmacol; 2020; 13(2):108-125. PubMed ID: 31657692
[TBL] [Abstract][Full Text] [Related]
18. Heparan sulfate-dependent enhancement of henipavirus infection.
Mathieu C; Dhondt KP; Châlons M; Mély S; Raoul H; Negre D; Cosset FL; Gerlier D; Vivès RR; Horvat B
mBio; 2015 Mar; 6(2):e02427. PubMed ID: 25759505
[TBL] [Abstract][Full Text] [Related]
19. Antiviral activity of membrane fusion inhibitors that target gp40 of the feline immunodeficiency virus envelope protein.
Mizukoshi F; Baba K; Goto Y; Setoguchi A; Fujino Y; Ohno K; Oishi S; Kodera Y; Fujii N; Tsujimoto H
Vet Microbiol; 2009 Apr; 136(1-2):155-9. PubMed ID: 19036536
[TBL] [Abstract][Full Text] [Related]
20. Heptad repeat 2 in herpes simplex virus 1 gH interacts with heptad repeat 1 and is critical for virus entry and fusion.
Gianni T; Piccoli A; Bertucci C; Campadelli-Fiume G
J Virol; 2006 Mar; 80(5):2216-24. PubMed ID: 16474129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
